Published in Vaccine Weekly, July 13th, 2005
According to recent research from Cuba, "Vibrio cholerae 638 is a living candidate cholera vaccine strain attenuated by deletion of the CTX Phi prophage from C7258 (O1, EI Tor Ogawa) and by insertion of the Clostridium thermocellum endoglucanase A gene into the hemagglutinin/protease coding sequence. This vaccine candidate was previously found to be well tolerated and immunogenic in volunteers.
"This article reports a randomized, double-blind, placebo-controlled trial conducted to test short-term protection conferred by 638 against...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-07-13)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.